Astellas Pharma Inc. (ALPMY) Thursday said it has signed an agreement with Sangamo Therapeutics, Inc. (SGMO) to leverage Sangamo's proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, to deliver genomic medicines to treat certain neurological diseases.
Astellas gets a worldwide exclusive license to utilize the STAC-BBB capsid for one target, with the right to add up to four additional targets after paying additional fees.
As per the deal, Sangamo will receive an upfront payment of $20 million, with earnout payments of up to $1.3 billion, as well as mid-to-high single digit royalties on potential net sales of the five potential disease targets.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.